Brief: Quantum-Si Q2 EPS USD -0.16

Quantum-Si

05/08/2025 21:05

Overview

Quantum-Si Q2 2025 revenue at $591,000, impacted by NIH funding challenges

Co raises $50 mln in capital, extending cash runway to Q2 2028

Product development on track with v4 Sequencing Kit launch in Q3 2025

Outlook

Company expects Q3 2025 launch of v4 Sequencing Kit

Quantum-Si plans Q4 2025 launch of v3 Library Preparation Kit

Company aims for successful protein sequencing on Proteus by end of 2025

Quantum-Si sees sufficient capital to operate into Q2 2028

Result Drivers

NIH FUNDING CHALLENGES - Co reports NIH funding issues slowed capital sales, impacting Q2 revenue

INSTRUMENT OPTIONS - Expanded instrument acquisition options launched to drive user base growth and consumable revenue

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
$591,000
Q2 EPS
-$0.16
Q2 Net Income
-$28.84 mln
Q2 Operating Expenses
$30.47 mln
Q2 Operating Income
-$30.12 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Quantum-Si Inc is $3.50, about 58.9% above its August 4 closing price of $1.44

Press Release: ID:nBw6lBLR4a

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)